Optimizing EphA2-CAR T Cells for the Adoptive Immunotherapy of Glioma

Optimizing EphA2-CAR T Cells for the Adoptive Immunotherapy of Glioma

Glioblastoma is the most aggressive primary brain tumor in humans and is virtually incurable with conventional therapies. Chimeric antigen receptor (CAR) T cell therapy targeting the glioblastoma antigen EphA2 is an attractive approach to improve outcomes because EphA2 is expressed highly in gliobla...

Full description

Bibliographic Details
Main Authors: Zhongzhen Yi, Brooke L. Prinzing, Felicia Cao, Stephen Gottschalk, Giedre Krenciute
Format: Article
Language:English
Published: Elsevier 2018-06-01
Series:Molecular Therapy: Methods & Clinical Development
Online Access:http://www.sciencedirect.com/science/article/pii/S232905011830010X

Similar Items

Similar Items